Research programme: metabolic disorders therapy - Kalypsys
Latest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator Kalypsys
- Class Small molecules
- Mechanism of Action Peroxisome proliferator-activated receptor delta agonists; Peroxisome proliferator-activated receptor gamma agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Metabolic disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Metabolic-disorders in USA
- 01 Sep 2005 Compounds from this programme are available for partnering (http://www.kalypsys.com)
- 01 Sep 2005 Kalypsys has selected compounds from this programme as lead candidates